|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.28 / 9.49|
The broad protection of these patents opens doors to partnerships in the world's second- and third-largest pharmaceutical markets
In trading on Tuesday, shares of Galectin Therapeutics Inc touched a new 52-week high of $6.74/share. That's a 617.02% rise, or $5.8 per share from the 52-week low of $0.94 set back on 01/23/2017.
Levi & Korsinsky announces it has commenced an investigation of Galectin Therapeutics, Inc.
Company to Host Investor Conference Call at 8:30 A.M. ET
The objective response rate in advanced melanoma was 62.5% (five of eight subjects)
Research to be presented demonstrates VCTE liver stiffness measurement is a surrogate for identifying portal hypertension in patients with compensated NASH cirrhosis
80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial
Patent supports the Combination Immunotherapy trial utilizing GR-MD-02, now completed enrollment of second ascending dose cohort
The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS
Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.